Jump to: navigation, search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Dirlotapide


Most recent articles on Dirlotapide

Most cited articles on Dirlotapide

Review articles on Dirlotapide

Articles on Dirlotapide in N Eng J Med, Lancet, BMJ


Powerpoint slides on Dirlotapide

Images of Dirlotapide

Photos of Dirlotapide

Podcasts & MP3s on Dirlotapide

Videos on Dirlotapide

Evidence Based Medicine

Cochrane Collaboration on Dirlotapide

Bandolier on Dirlotapide

TRIP on Dirlotapide

Clinical Trials

Ongoing Trials on Dirlotapide at Clinical Trials.gov

Trial results on Dirlotapide

Clinical Trials on Dirlotapide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Dirlotapide

NICE Guidance on Dirlotapide


FDA on Dirlotapide

CDC on Dirlotapide


Books on Dirlotapide


Dirlotapide in the news

Be alerted to news on Dirlotapide

News trends on Dirlotapide


Blogs on Dirlotapide


Definitions of Dirlotapide

Patient Resources / Community

Patient resources on Dirlotapide

Discussion groups on Dirlotapide

Patient Handouts on Dirlotapide

Directions to Hospitals Treating Dirlotapide

Risk calculators and risk factors for Dirlotapide

Healthcare Provider Resources

Symptoms of Dirlotapide

Causes & Risk Factors for Dirlotapide

Diagnostic studies for Dirlotapide

Treatment of Dirlotapide

Continuing Medical Education (CME)

CME Programs on Dirlotapide


Dirlotapide en Espanol

Dirlotapide en Francais


Dirlotapide in the Marketplace

Patents on Dirlotapide

Experimental / Informatics

List of terms related to Dirlotapide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Dirlotapide is a drug used to treat obesity in dogs. It is manufactured by Pfizer and marketed as Slentrol.

It works as a selective microsomal triglyceride transfer protein (MTTP) inhibitor. This blocks the assembly and release of lipoproteins into the bloodstream, thereby reducing fat absorption. It also elicits a satiety signal from lipid-filled cells lining the intestine.

It is supplied as an oral solution. It is not intended for use in humans, cats, or parrots.

On January 5, 2007, the U.S. Food and Drug Administration (FDA) approved Slentrol, the first time the FDA has approved a drug for obese dogs. Dirlotapide is used to manage obesity in dogs and helps by reducing appetite. It should be used as part of an overall weight control program that also includes proper diet and exercise, under the supervision of a veterinarian. Side effects may include vomiting, diarrhea, lethargy, drooling, or uncoordination. Allergic reaction to the medication may include, facial swelling, hives, scratching, sudden onset of diarrhea, vomiting, shock, seizures, pale gums, cold limbs, or coma. Contact your veterinarian if you observe any of these signs. The dose of dirlotapide will need to be recalculated each month, based on your dog's weight.